Cingulate therapeutics filing
WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing. WebMay 31, 2024 · Cingulate anticipates filing INDs for CTX-1301 and CTX-1302 via the accelerated 505 (b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information ...
Cingulate therapeutics filing
Did you know?
WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … The Investor Relations website contains information about Cingulate Inc's …
WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... WebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ...
WebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer ... WebFunding. Cingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO.
WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: Third Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Kansas City: …
WebMar 30, 2024 · (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on ... the ranch kamloopsWeb8 rows · Jun 29, 2024 · Cingulate Therapeutics - Most recent fund raising on June 29, 2024 raised $7,000,000 in Equity and Debt the ranch leedsWebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated … the ranch inn jackson wysigns jesus is the reason for the seasonWebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead … the ranch in irving texas restaurantWebCingulate Therapeutics is based out of Morristown. The firm last filed a Form D notice of exempt offering of securities on 2024-06-29. The notice included securities offered of … the ranch in nashville tnWebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate … signs job isn’t right fit